baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

Soc. Generale Knock-Out ABBV/ DE000CJ5P0T9 /

2024-05-17 9:25:51 PM	Chg.+0.170	Bid2024-05-17	Ask2024-05-17	Underlying	Strike price	Expiration date	Option type
11.580EUR	+1.49%	11.580 Bid Size: 60,000	11.590 Ask Size: 60,000	AbbVie Inc	41.1881 USD	2078-12-31	Call

GlobeNewswire 1:12 PM INVESTIGATION ANNOUNCEMENT: BFA Law Announces an Ongoing Investigation into the Merger between Cerev...

GlobeNewswire 05-16 CytomX Therapeutics Announces New Employment Inducement Grants

GlobeNewswire 05-16 Ventyx Biosciences Announces Appointment of Matthew Moore as Chief Operating Officer

GlobeNewswire 05-14 CEREVEL THERAPEUTICS HOLDINGS, INC. (NASDAQ: CERE) INVESTIGATION ALERT: Is $45 per CERE Share Enough...

GlobeNewswire 05-14 Pyxis Oncology Provides Corporate Update and Reports Financial Results for First Quarter 2024

GlobeNewswire 05-14 Nouscom Appoints Leading Cancer Drug Development Expert, Neil Gallagher, MD, PhD, as Independent Adv...

GlobeNewswire 05-14 In NCLA Amicus Win, and FTC Amicus Loss, Second Circuit Upholds Decision Dismissing Antitrust Suit

GlobeNewswire 05-13 Royalty Pharma to Present at Upcoming Investor Conferences

GlobeNewswire 05-11 SHAREHOLDER NOTICE: Halper Sadeh LLC Investigates LABP, DOMA, FXNC

GlobeNewswire 05-09 Coherus Announces Full Repayment of Pharmakon Advisors $75 Million Term Loan

GlobeNewswire 05-09 Royalty Pharma Reports First Quarter 2024 Results

GlobeNewswire 05-09 Royalty Pharma to Acquire Royalty Interest in Sanofi’s Frexalimab

GlobeNewswire 05-09 Nxera Pharma’s partner Neurocrine Biosciences Initiates Phase 1 Clinical Study Evaluating Effects of...

GlobeNewswire 05-08 CytomX Therapeutics Announces Positive Initial Phase 1a Dose Escalation Data for Monotherapy CX-904 ...

GlobeNewswire 05-08 CytomX Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

GlobeNewswire 05-08 Alector Reports First Quarter 2024 Financial Results and Provides Business Update

GlobeNewswire 05-08 Coherus Announces Clinical Collaboration with the Cancer Research Institute for a Novel Combination ...

GlobeNewswire 05-08 Jnana Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference

GlobeNewswire 05-08 ArriVent BioPharma Reports First Quarter 2024 Financial Results

GlobeNewswire 05-07 CytomX Therapeutics Announces Clinical Collaboration with Merck to Evaluate CX-801 in Combination wi...

GlobeNewswire 05-07 Caribou Biosciences Reports First Quarter 2024 Financial Results and Provides Business Update

GlobeNewswire 05-06 Pacific Software Inc. Announces a Landmark Asset Acquisition from Dreamaderm Inc.

GlobeNewswire 05-02 Genmab Announces Financial Results for the First Quarter of 2024

GlobeNewswire 05-02 Aprea Therapeutics Announces Appointment of Nadeem Q. Mirza, M.D., M.P.H. as Chief Medical Officer a...

GlobeNewswire 05-01 CytomX Therapeutics to Report First Quarter 2024 Results and Provide an Initial CX-904 Phase 1a Clin...

Soc. Generale Knock-Out ABBV/ DE000CJ5P0T9 /

If you wish to receive reply to your feedback, please provide your email address.